Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.

Four-factor prothrombin complex concentrate (4F-PCC) is indicated for vitamin K antagonist (VKA) reversal but is associated with thrombotic events (TE). In 2018, the institution revised 4F-PCC dosing for VKA reversal from INR and weight-based dosing to a fixed-dose of 1500 units. The purpose of this study was to compare hemostatic efficacy and TE rate of fixed-dose 4PCC to weight-based dosing.

Incidence of Hyponatremia Among Critically Ill Patients With and Without COVID-19 Infection at a Community Teaching Hospital.

Various studies have demonstrated the incidence of hyponatremia in patients with Coronavirus Disease 2019 (COVID-19); however, to our knowledge, no study has assessed the difference in the incidence of hyponatremia in patients with and without COVID-19. To compare the incidence of hyponatremia in patients requiring intensive care unit (ICU) admission with and without COVID-19 infection. This was a single-center, retrospective cohort study of patients with a diagnosis of pneumonia from February 2019 to January 2020, or a diagnosis of COVID-19 from June 2020 to May 2021.

Use of Systemic Bivalirudin and an Anticoagulant-Free Purge Solution in a Percutaneous Left Ventricular Assist Device in a Patient With Heparin-Induced Thrombocytopenia.

The use of systemic bivalirudin and an anticoagulant-free purge solution in a percutaneous left ventricular assist device (pVAD) is described in a patient with a history of heparin-induced thrombocytopenia (HIT). An 80-year-old man with a past medical history of severe aortic stenosis and HIT was transferred to our facility for cardiogenic shock. The patient was emergently taken to the cardiac catheterization laboratory for balloon valvuloplasty and Impella pVAD (Abiomed, Inc) implantation.